Globeimmune Inc logo

GBIM - Globeimmune Inc Share Price

$0.4 -0.1  -16.6%

Last Trade - 10/07/20

Sector
Healthcare
Size
Micro Cap
Market Cap £1.82m
Enterprise Value £-5.07m
Revenue £4.92m
Position in Universe th / 6339
Bullish
Bearish
Unlock GBIM Revenue
Momentum
Relative Strength (%)
1m +404.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -17.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2010 2011 2012 2013 2014 2015 2016E 2017E CAGR / Avg
4.07 5.11 14.6 22.5 5.97 6.46 +9.7%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2016, GlobeImmune Inc revenues decreased 21% to $943K. Net loss decreased 45% to $862K. Revenues reflect Manufacturing services decrease from $161K to $0K, Collaboration license and services decrease of 8% to $943K. Lower net loss reflects Costs of collaboration license and servi decrease of 44% to $515K (expense), General and administrative decrease of 22% to $933K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

GBIM Revenue Unlock GBIM Revenue

Net Income

GBIM Net Income Unlock GBIM Revenue

Normalised EPS

GBIM Normalised EPS Unlock GBIM Revenue

PE Ratio Range

GBIM PE Ratio Range Unlock GBIM Revenue

Dividend Yield Range

GBIM Dividend Yield Range Unlock GBIM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
GBIM EPS Forecasts Unlock GBIM Revenue
Profile Summary

GlobeImmune, Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company's segment is the business of developing and commercializing various biopharmaceutical products. The Company's infectious disease product candidates include GS-4774, which is in Phase II for the treatment of chronic hepatitis B infection; GI-19000; GI-2010, which is in the preclinical stage of development for the treatment of Human immunodeficiency virus (HIV), and GI-18000, which is in the preclinical stage of development for the treatment of Chronic hepatitis D infection. The Company's oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, and GI-4000, which is in Phase IIb for the treatment of Resected pancreas cancer, and in Phase II for the treatment of Non-small cell lung cancer and colorectal cancer.

Directors
Last Annual December 31st, 2015
Last Interim March 31st, 2016
Incorporated June 5, 2002
Public Since July 2, 2014
No. of Shareholders: n/a
No. of Employees: 22
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OTC Markets Group
Shares in Issue 5,751,574
Free Float (0.0%)
Eligible for
ISAs
SIPPs
GBIM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for GBIM
Upcoming Events for GBIM
Frequently Asked Questions for Globeimmune Inc
What is the Globeimmune Inc share price?

As of 10/07/20, shares in Globeimmune Inc are trading at $0.4, giving the company a market capitalisation of £1.82m. This share price information is delayed by 15 minutes.

How has the Globeimmune Inc share price performed this year?

Shares in Globeimmune Inc are currently trading at $0.4 and the price has moved by 0.313k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Globeimmune Inc price has moved by 0.311k% over the past year.

What are the analyst and broker recommendations for Globeimmune Inc?

There are no analysts currently covering Globeimmune Inc.

When will Globeimmune Inc next release its financial results?

Globeimmune Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2017-03-31
What is the Globeimmune Inc dividend yield?

Globeimmune Inc does not currently pay a dividend.

Does Globeimmune Inc pay a dividend?

Globeimmune Inc does not currently pay a dividend.

When does Globeimmune Inc next pay dividends?

Globeimmune Inc does not currently pay a dividend.

How do I buy Globeimmune Inc shares?

To buy shares in Globeimmune Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Globeimmune Inc?

Shares in Globeimmune Inc are currently trading at $0.4, giving the company a market capitalisation of £1.82m.

Where are Globeimmune Inc shares listed? Where are Globeimmune Inc shares listed?

Here are the trading details for Globeimmune Inc:

Country of listing: United States
Exchange: OTC
Ticker Symbol: GBIM
What kind of share is Globeimmune Inc?

We were not able to load our ranking data for Globeimmune Inc

Is there a Globeimmune Inc share price forecast 2020?

We were not able to load any forecast data for Globeimmune Inc.

How can I tell whether the Globeimmune Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Globeimmune Inc. Over the past six months, the relative strength of its shares against the market has been 0.386k%. At the current price of $0.4, shares in Globeimmune Inc are trading at 0.275k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Globeimmune Inc PE Ratio?

We were not able to find PE ratio data for Globeimmune Inc.

Who are the key directors of Globeimmune Inc?

Globeimmune Inc's management team is headed by:

J. William Freytag - CHM
C. Jeffrey Dekker - VFN
Daniel Mitchell - IND
Timothy Rodell - CEO
S. Edward Torres - IND
Augustine Lawlor - IND
Who are the major shareholders of Globeimmune Inc?

Here are the top five shareholders of Globeimmune Inc based on the size of their shareholding:

Invesco Capital Management LLC Investment Advisor
Percentage owned: 0.02% (1.02k shares)
Invesco Wilshire Micro-Cap ETF Mutual Fund
Percentage owned: 0.02% (1.02k shares)
Similar to GBIM
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.